Invention Grant
- Patent Title: N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds
-
Application No.: US15749652Application Date: 2016-08-04
-
Publication No.: US10479785B2Publication Date: 2019-11-19
- Inventor: Shudong Wang , Solomon Tadesse Zeleke , Mingfeng Yu
- Applicant: UNIVERSITY OF SOUTH AUSTRALIA
- Applicant Address: AU Dulwich
- Assignee: AUCENTRA THERAPEUTICS PTY LTD
- Current Assignee: AUCENTRA THERAPEUTICS PTY LTD
- Current Assignee Address: AU Dulwich
- Agency: Meunier Carlin & Curfman LLC
- Priority: AU2015903106 20150804
- International Application: PCT/AU2016/000269 WO 20160804
- International Announcement: WO2017/020065 WO 20170209
- Main IPC: C07D417/14
- IPC: C07D417/14 ; A61P35/02
Abstract:
A novel class of inhibitors of protein kinases that are useful in the treatment of cell proliferative diseases and conditions, and especially those characterised by over-expression of CDK4, CDK6 and/or cyclin D, including certain cancers of lung, breast, brain, central nervous system, colorectal cancer and leukaemias. The inhibitors have the general structure I:
Public/Granted literature
- US20180222900A1 N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS Public/Granted day:2018-08-09
Information query
